Cite
HARVARD Citation
Knox, J. et al. (n.d.). P-217A phase 3 study of durvalumab with or without bevacizumab as adjuvant therapy in patients with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation: EMERALD-2. Annals of oncology. p. . [Online].